| Literature DB >> 30952886 |
Dina Nada1,2, Cédric Julien1, Pierre H Rompré3, Marie-Yvonne Akoume1, Kristen F Gorman1,4, Mark E Samuels5,6, Emile Levy5,7, Jason Kost8, Dawei Li8,9, Alain Moreau10,11,12,13.
Abstract
The cellular and molecular mechanisms underlying spinal deformity progression in adolescent idiopathic scoliosis (AIS) remain poorly understood. In this study, 804 French-Canadian patients and 278 age- and sex-matched controls were enrolled and genotyped for 12 single nucleotide polymorphisms (SNPs) in the chitinase 3-like 1 (CHI3L1) gene or its promoter. The plasma YKL-40 levels were determined by ELISA. We showed that elevation of circulating YKL-40 levels was correlated with a reduction of spinal deformity progression risk. We further identified significant associations of multiple CHI3L1 SNPs and their haplotypes with plasma YKL-40 levels and scoliosis severity as a function of their classification in a specific endophenotype. In the endophenotype FG3 group, we found that patients harboring the haplotype G-G-A-G-G-A (rs880633|rs1538372|rs4950881|rs10399805|rs6691378|rs946261), which presented in 48% of the cases, showed a positive correlation with the plasma YKL-40 levels (P = 7.6 × 10-6 and coefficient = 36). Conversely, the haplotype A-A-G-G-G-G, which presented in 15% of the analyzed subjects, showed a strong negative association with the plasma YKL-40 levels (P = 2 × 10-9 and coefficient = -9.56). We found that this haplotype showed the strongest association with AIS patients in endophenotype FG2 (P = 9.9 × 10-6 and coefficient = -13.53), who more often develop severe scoliosis compared to those classified in the other two endophenotypes. Of note, it showed stronger association in females (P = 1.6 × 10-7 and coefficient = -10.08) than males (P = 0.0021 and coefficient = -9.01). At the functional level, we showed that YKL-40 treatments rescued Gi-coupled receptor signalling dysfunction occurring in primary AIS osteoblasts. Collectively, our findings reveal a novel role for YKL-40 in AIS pathogenesis and a new molecular mechanism interfering with spinal deformity progression.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30952886 PMCID: PMC6450973 DOI: 10.1038/s41598-019-41191-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Clinical and biochemical characteristics of participants.
| Groups | Females | Males | All Subjects | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Mean Age (Years) | Mean Cobb Angle (°) | YKL-40 (ng/ml) | Mean Age (Years) | Mean Cobb Angle (°) | YKL-40 (ng/ml) | Mean Age (Years) | Mean Cobb Angle (°) | YKL-40 (ng/ml) | |
| All AIS | 13.7 ± 2.2 (6.9–26.0) | 28 ± 16 (10–90) | 32 ± 20 (3–326) | 14.0 ± 2.1 (7.4–18.2) | 22 ± 11 (10–72) | 39 ± 36 (8–298) | 13.8 ± 2.2 (6.9–26.0) | 27 ± 16 (10–90) | 33 ± 23 |
| N = 598 | N = 112 | N = 710 | |||||||
| Endophenotype | 13.5 ± 2.1 (6.9–18.7) | 28 ± 15 (10–83) | 30 ± 12 (5–69) | 14.2 ± 1.6 (10.9–16.7) | 27 ± 20 (10–76) | 57 ± 62 (14–298) | 13.6 ± 2.0 (6.9–18.7) | 28 ± 16 (10–83) | 34 ± 27 |
| N = 124 | N = 21 | N = 145 | |||||||
| EndophenotypeFG2 | 13.8 ± 2.2 (7.3–19.1) | 30 ± 17 (10–89) | 32 ± 19 (3–183) | 14.0 ± 2.6 (8.7–18.2) | 24 ± 12 (10–56) | 36 ± 39 (9–228) | 13.9 ± 2.2 (7.3–19.1) | 29 ± 17 (10–89) | 32 ± 22 |
| N = 229 | N = 28 | N = 257 | |||||||
| EndophenotypeFG3 | 13.6 ± 2.2 (7.7–26.0) | 26 ± 15 (10–90) | 33 ± 24 (4–326) | 14.0 ± 2.3 (7.4–18.2) | 22 ± 14 (10–66) | 33 ± 16 (8–96) | 13.7 ± 2.2 (7.4–26.0) | 25 ± 14 (10–90) | 33 ± 23 |
| N = 241 | N = 60 | N = 301 | |||||||
| Healthy Control Subjects | 12.5 ± 3.3 (7.1–18.3) | NA | 29 ± 13 (8–81) | 12.4 ± 3.1 (7.2–17.6) | NA | 28 ± 13 (4–90) | 12.5 ± 3.2 (7.1–18.3) | NA | 29 ± 13 |
| N = 124 | N = 103 | N = 227 | |||||||
Figure 1Plasma YKL-40 levels in function of sex and AIS biological endophenotypes. An ANOVA, two-sided T-test was applied and the presented p-values were after Bonferroni adjustment for pair wise comparisons.
Prevalence of the studied SNPs in CHI3L1 gene and their associations with plasma YKL-40 levels in AIS patients and healthy controls.
| SNP | Controls | AIS | ||||
|---|---|---|---|---|---|---|
| (N = 216) | Mean YKL-40 (ng/ml) ± SD (95% CI) | P value | (N = 728) | Mean YKL-40 (ng/ml) ± SD (95% CI) | P value | |
|
| 0.028 | |||||
| CC | 44 (20%) | 26 ± 12 (22–30) | 167 (23%) | 27 ± 12 (25–29) | ||
| CA | 111 (51%) | 28 ± 11 (26–30) | 384 (53%) | 34 ± 28 (31–37) | ||
| AA | 61 (28%) | 31 ± 16 (27–36) | 175 (24%) | 38 ± 20 (35–42) | ||
|
| 0.11 | 0.952 | ||||
| GG | 160 (74%) | 28 ± 12 (26–30) | 494 (68%) | 33 ± 23 (31–35) | ||
| GA | 52 (24%) | 30 ± 13 (26–34) | 212 (29%) | 34 ± 27 (30–38) | ||
| AA | 3 (1%) | 35 ± 24 (8–63) | 22 (3%) | 32 ± 11 (27–36) | ||
|
| 0.026 | |||||
| GG | 43 (20%) | 26 ± 12 (22–30) | 164 (23%) | 27 ± 12 (25–29) | ||
| GA | 109 (51%) | 28 ± 11 (26–30) | 386 (53%) | 34 ± 28 (31–37) | ||
| AA | 63 (29%) | 31 ± 16 (27–35) | 177 (24%) | 38 ± 20 (35–41) | ||
|
| 0.025 | |||||
| GG | 63 (29%) | 31 ± 16 (35–41) | 177 (24%) | 31 ± 16 (27–35) | ||
| GA | 110 (51%) | 27 ± 11 (31–37) | 387 (53%) | 27 ± 11 (25–29) | ||
| AA | 43 (20%) | 26 ± 12 (25–29) | 164 (22%) | 26 ± 12 (22–30) | ||
|
|
| |||||
| GG | 97 (45%) | 31 ± 15 (28–34) | 318 (44%) | 38 ± 25(35–41) | ||
| GA | 98 (45%) | 27 ± 10 (25–29) | 327 (45%) | 31 ± 24 (28–34) | ||
| AA | 21 (10%) | 22 ± 9 (19–26) | 75 (10%) | 24 ± 12 (21–27) | ||
|
| 0.029 | |||||
| GG | 12 (6%) | 26 ± 9 (20–31) | 48 (7%) | 22 ± 12 (19–26) | ||
| GA | 80 (37%) | 26 ± 9 (21–32) | 256 (35%) | 32 ± 26 (28–35) | ||
| AA | 123 (57%) | 30 ± 15 (27–33) | 423 (58%) | 35 ± 23 (33–38) | ||
|
| 0.124 | 0.523 | ||||
| GG | 164 (76%) | 28 ± 12 (26–30) | 518 (71%) | 33 ± 22 (31–35) | ||
| GA | 49 (23%) | 31 ± 13 (27–35) | 189 (26%) | 34 ± 28 (30–39) | ||
| AA | 2 (1%) | 24 ± 3 (20–28) | 18 (2%) | 33 ± 11 (25–41) | ||
|
| 0.107 | 0.482 | ||||
| GG | 166 (77%) | 28 ± 12 (26–30) | 520 (72%) | 33 ± 22 (31–35) | ||
| GA | 47 (22%) | 30 ± 12 (26–34) | 189 (26%) | 35 ± 28 (31–39) | ||
| AA | 2 (1%) | 42 ± 29 (2–82) | 18 (2%) | 31 ± 9 (27–35) | ||
|
| 0.036 | |||||
| AA | 79 (38%) | 30 ± 12 (28–33) | 258 (35%) | 39 ± 27 (36–43) | ||
| AG | 107 (52%) | 26 ± 10 (24–28) | 355 (49%) | 31 ± 23 (29–34) | ||
| GG | 21 (10%) | 26 ± 14 (20–32) | 115 (16%) | 25 ± 11(23–27) | ||
|
|
| |||||
| GG | 146 (68%) | 30 ± 14 (28–32) | 477 (66%) | 38 ± 27 (35–40) | ||
| GA | 65 (30%) | 25 ± 9 (23–27) | 224 (31%) | 26 ± 14 (24–28) | ||
| AA | 5 (2%) | 19 ± 6 (13–25) | 24 (3%) | 16 ± 10 (12–20) | ||
|
| 0.816 | 0.645 | ||||
| GG | 214 (99%) | 28 ± 13 (26–30) | 711 (98%) | 33 ± 24 (31–35) | ||
| GA | 2 (1%) | 26 ± 14 (7–45) | 16 (2%) | 30 ± 8 (26–35) | ||
|
| 0.01 | |||||
| GG | 158 (74%) | 30 ± 14 (27–32) | 518 (71%) | 36 ± 26 (34–39) | ||
| GA | 53 (25%) | 25 ± 9 (22–28) | 187 (26%) | 26 ± 14 (24–28) | ||
| AA | 4 (2%) | 22 ± 4 (8–36) | 22 (3%) | 16 ± 10 (12–21) | ||
P ≤ 0.004 is considered significant after Bonferroni correction.
Prevalence of the studied SNPs in CHI3L1 gene and their associations with plasma YKL-40 levels in function of scoliosis severity.
| SNP | AIS severe (Cobb ≥ 40°) | P value | AIS non-severe (Cobb < 40°) | P value | ||
|---|---|---|---|---|---|---|
| N = 132 | Mean YKL-40 (ng/ml) ± SD (95% CI) | N = 227 | Mean YKL-40 (ng/ml) ± SD (95% CI) | |||
|
| 0.008 | |||||
| CC | 38 (29%) | 29 ± 12 (24–33) | 57 (25%) | 25 ± 10 (22–28) | ||
| CA | 68 (52%) | 30 ± 15 (26–34) | 107 (47%) | 33 ± 14 (30–36) | ||
| AA | 26 (20%) | 40 ± 12 (35–45) | 63 (28%) | 39 ± 20 (34–45) | ||
|
| 0.651 | 0.69 | ||||
| GG | 93 (70%) | 32 ± 15 (29–35) | 152 (67%) | 33 ± 19 (30–36) | ||
| GA | 39 (30%) | 30 ± 12 (26–35) | 67 (30%) | 31 ± 10 (29–34) | ||
| AA | 0 | 8 (4%) | 29 ± 7 (25–34) | |||
|
| 0.008 | |||||
| GG | 37 (28%) | 28 ± 12 (24–33) | 57 (25%) | 25 ± 10 (22–28) | ||
| GA | 68 (52%) | 30 ± 15 (26–34) | 106 (47%) | 33 ± 14 (30–36) | ||
| AA | 27 (20%) | 39 ± 12 (34–44) | 63 (28%) | 39 ± 20 (34–45) | ||
|
| 0.008 | |||||
| GG | 27 (20%) | 39 ± 12 (34–44) | 63 (28%) | 39 ± 20 (34–45) | ||
| GA | 68 (52%) | 30 ± 15 (26–34) | 107 (47%) | 33 ± 14 (30–36) | ||
| AA | 37 (28%) | 28 ± 12 (24–33) | 57 (25%) | 25 ± 10 (22–28) | ||
|
| 0.012 |
| ||||
| GG | 50 (38%) | 37 ± 13 (33–41) | 100 (45%) | 37 ± 16 (34–40) | ||
| GA | 59 (45%) | 28 ± 14 (24–32) | 97 (44%) | 31 ± 15 (27–34) | ||
| AA | 23 (17%) | 29 ± 13 (23–34) | 25 (11%) | 22 ± 12 (17–27) | ||
|
| 0.012 | |||||
| GG | 17 (13%) | 25 ± 12 (19–31) | 15 (7%) | 19 ± 11 (13–24) | ||
| GA | 52 (39%) | 30 ± 15 (25–35) | 80 (35%) | 30 ± 16 (26–34) | ||
| AA | 63 (48%) | 35 ± 13 (31–38) | 132 (58%) | 36 ± 16 (33–39) | ||
|
| 0.695 | 0.353 | ||||
| GG | 99 (76%) | 31 ± 14 (28–34) | 165 (73%) | 33 ± 18 (30–36) | ||
| GA | 30 (23%) | 31 ± 12 (26–37) | 56 (25%) | 31 ± 10 (28–34) | ||
| AA | 1 (1%) | 20 | 6 (3%) | 31 ± 7 (25–36) | ||
|
| 0.626 | 0.364 | ||||
| GG | 100 (76%) | 32 ± 14 (29–35) | 165 (73%) | 33 ± 18 (30–36) | ||
| GA | 30 (23%) | 31 ± 12 (26–37) | 56 (25%) | 31 ± 10 (28–34) | ||
| AA | 1 (1%) | 20 | 6 (3%) | 31 ± 7 (25–36) | ||
|
| 0.079 | |||||
| AA | 45 (34%) | 34 ± 14 (30–39) | 87 (38%) | 40 ± 20 (36–45) | ||
| AG | 67 (51%) | 31 ± 14 (27–35) | 102 (45%) | 29 ± 11 (27–32) | ||
| GG | 20 (15%) | 27 ± 12 (21–33) | 38 (17%) | 24 ± 11 (20–28) | ||
|
| 0.023 | |||||
| GG | 78 (60%) | 35 ± 13 (31–38) | 149 (66%) | 37 ± 17 (34–40) | ||
| GA | 47 (36%) | 28 ± 14 (23–32) | 69 (30%) | 25 ± 9 (23–28) | ||
| AA | 5 (4%) | 26 ± 15 (11–42) | 8 (4%) | 9 ± 4 (8–10) | ||
|
| 0.921 | 0.619 | ||||
| GG | 131 (99%) | 31 ± 14 (29–34) | 223 (98%) | 33 ± 16 (30–35) | ||
| GA | 1 (1%) | 30 | 4 (2%) | 27 ± 14 (10–41) | ||
|
| 0.08 | |||||
| GG | 85 (64%) | 33 ± 13 (30–36) | 164 (72%) | 36 ± 17 (33–38) | ||
| GA | 41 (31%) | 29 ± 15 (24–34) | 57 (25%) | 26 ± 9 (24–29) | ||
| AA | 6 (4%) | 23 ± 15 (10–37) | 6 (3%) | 9 ± 4 (5–13) | ||
P ≤ 0.002 is considered significant after Bonferroni correction.
Prevalence of the studied SNPs in CHI3L1 gene and their associations with plasma YKL-40 levels in function of AIS biological endophenotypes.
| SNP | FG1 | P value | FG2 | P value | FG3 | P value | |||
|---|---|---|---|---|---|---|---|---|---|
| (N = 146) | Mean YKL-40 (ng/ml) ± SD (95% CI) | (N = 240) | Mean YKL-40 (ng/ml) ± SD (95% CI) | (N = 286) | Mean YKL-40 (ng/ml) ± SD (95% CI) | ||||
|
| 0.186 | 0.035 | |||||||
| CC | 27 (18%) | 28 ± 14 (22–33) | 65 (27%) | 25 ± 10 (23–28) | 66 (23%) | 28 ± 14 (25–32) | |||
| CA | 78 (53%) | 34 ± 34 (26–42) | 123 (52%) | 33 ± 26 (28–38) | 153 (54%) | 34 ± 28 (30–39) | |||
| AA | 41 (28%) | 37 ± 19 (32–43) | 50 (21%) | 40 ± 24 (33–47) | 67 (23%) | 37 ± 16 (33–41) | |||
|
| 0.613 | 0.68 | 0.98 | ||||||
| GG | 90 (62%) | 33 ± 18 (29–36) | 170 (71%) | 32 ± 22 (29–36) | 196 (68%) | 34 ± 26 (30–37) | |||
| GA | 53 (36%) | 36 ± 40 (25–48) | 60 (25%) | 32 ± 28 (25–39) | 81 (28%) | 33 ± 14 (30–36) | |||
| AA | 3 (2%) | 28 ± 8 (19–38) | 10 (4%) | 29 ± 6 (25–33) | 9 (3%) | 36 ± 15 (26–46) | |||
|
| 0.19 | 0.03 | |||||||
| GG | 27 (19%) | 28 ± 14 (22–33) | 65 (27%) | 25 ± 10 (23–28) | 63 (22%) | 28 ± 14 (24–32) | |||
| GA | 77 (53%) | 34 ± 34 (26–42) | 123 (51%) | 33 ± 26 (28–38) | 156 (54%) | 34 ± 27 (30–39) | |||
| AA | 41 (28%) | 37 ± 19 (32–43) | 52 (22%) | 40 ± 24 (33–46) | 67 (23%) | 37 ± 16 (33–41) | |||
|
| 0.19 | 0.03 | |||||||
| GG | 41 (28.1%) | 37 ± 19 (32–43 | 52 (22%) | 40 ± 24 (33–46) | 67 (23%) | 37 ± 16 (33–41) | |||
| GA | 78 (53%) | 34 ± 34 (26–42) | 123 (51%) | 33 ± 26 (28–38) | 156 (54%) | 34 ± 27 (30–39) | |||
| AA | 27 (18%) | 28 ± 14 (22–33) | 65 (27%) | 25 ± 10 (23–28) | 63 (22%) | 28 ± 14 (24–32) | |||
|
| 0.045 | 0.015 | |||||||
| GG | 79 (54%) | 38 ± 34 (30–46) | 83 (36%) | 38 ± 29 (32–45) | 125 (44%) | 36 ± 15 (34–39) | |||
| GA | 56 (39%) | 29 ± 15 (25–33) | 123 (53%) | 30 ± 19 (27–34) | 128 (45%) | 33 ± 30 (27–38) | |||
| AA | 10 (7%) | 26 ± 15 (16–37) | 27 (12%) | 22 ± 9 (18–26) | 33 (12%) | 25 ± 14 (20–30) | |||
|
| 0.079 | 0.016 | 0.091 | ||||||
| GG | 4 (3%) | 17 ± 9 (7–26) | 17 (7%) | 21 ± 9 (17–26) | 23 (8%) | 24 ± 14 (18–30) | |||
| GA | 51 (35%) | 30 ± 17 (26–35) | 94 (39%) | 30 ± 22 (26–35) | 97 (34%) | 34 ± 34 (27–41) | |||
| AA | 91 (62%) | 37 ± 32 (27–44) | 129 (54%) | 35 ± 25 (31–39) | 165 (58%) | 34 ± 14 (32–37) | |||
|
| 0.436 | 0.93 | 0.591 | ||||||
| GG | 95 (65%) | 32 ± 18 (29–36) | 177 (74%) | 32 ± 22 (29–36) | 208 (73%) | 33 ± 25 (29–37) | |||
| GA | 49 (34%) | 38 ± 42 (25–50) | 53 (22%) | 33 ± 29 (25–41) | 69 (24%) | 33 ± 14 (30–36) | |||
| AA | 2 (1%) | 24 ± 3 (20–28) | 9 (4%) | 28 ± 7 (24–33) | 7 (2%) | 42 ± 12 (32–52) | |||
|
| 0.378 | 0.972 | 0.599 | ||||||
| GG | 95 (65%) | 32 ± 18 (26–38) | 178 (74%) | 32 ± 22 (28–35) | 209 (73%) | 33 ± 25 (30–37) | |||
| GA | 49 (34%) | 38 ± 41 (26–50) | 52 (22%) | 34 ± 29 (26–42) | 70 (25%) | 34 ± 15 (31–38) | |||
| AA | 2 (1%) | 24 ± 3 (20–27) | 10 (4%) | 28 ± 6 (24–32) | 6 (2%) | 39 ± 10 (30–48) | |||
|
| 0.133 | ||||||||
| AA | 54 (37%) | 36 ± 18 (31–41) | 77 (32%) | 41 ± 24 (35–6) | 106 (37%) | 40 ± 33 (34–46) | |||
| AG | 70 (48%) | 36 ± 36 (27–44) | 115 (48%) | 29 ± 25 (25–34) | 140 (49%) | 31 ± 13 (29–33) | |||
| GG | 22 (15%) | 23 ± 10 (19–28) | 48 (20%) | 25 ± 10 (22–28) | 40 (14%) | 25 ± 13 (21–30) | |||
|
| 0.03 |
| |||||||
| GG | 103 (70%) | 37 ± 31 (31–43) | 138 (58%) | 38 ± 26 (33–40) | 195 (69%) | 38 ± 26 (36–40) | |||
| GA | 39 (27%) | 28 ± 16 (23–33) | 93 (39%) | 25 ± 17 (22–29) | 79 (28%) | 25 ± 9 (23–27) | |||
| AA | 4 (3%) | 15 ± 8 (6–23) | 8 (3%) | 15 ± 6 (10–19) | 10 (4%) | 17 ± 12 (13–21) | |||
|
| 0.865 | 0.977 | 0.583 | ||||||
| GG | 145 (99%) | 34 ± 28 (29–39) | 235 (98%) | 32 ± 23 (29–35) | 276 (97%) | 34 ± 23 (31–36) | |||
| GA | 1 (1%) | 29.31 | 5 (2%) | 32 ± 8 (26–39) | 9 (3%) | 29 ± 10 (23–36) | |||
|
| 0.036 | ||||||||
| GG | 109 (75%) | 36 ± 30 (31–42) | 162 (68%) | 35 ± 25 (31–39) | 206 (72%) | 37 ± 25 (33–40) | |||
| GA | 33 (23%) | 28 ± 16 (22–33) | 71 (30%) | 26 ± 18 (22–31) | 70 (25%) | 25 ± 9 (23–27) | |||
| AA | 4 (3%) | 145 ± 8 (6–23) | 7 (3%) | 15 ± 6 (10–20) | 9 (3%) | 18 ± 13 (9–26) | |||
P ≤ 0.001 is considered significant after Bonferroni correction.
Figure 2Linkage disequilibrium blocks of the 12 SNPs tested in CHI3L1 gene.
Haplotype association analyses of plasma YKL-40 levels
| SNP IDs | SNPs | Haplotype | Freq | Coeff | Std. Error | Pr(>|t|) |
|---|---|---|---|---|---|---|
| rs55700740|rs7542294|rs946259|rs880633|rs1538372|rs4950881 | 1-2-3-4-5-6 | C-G-G-A-A-A | 0.074 | −5.93 | 2.09 | |
| rs7542294|rs946259|rs880633|rs1538372|rs4950881|rs10399805 | 2-3-4-5-6-7 | G-G-A-A-A-G | 0.069 | −5.13 | 2.12 | |
| rs946259|rs880633|rs1538372|rs4950881|rs10399805|rs6691378 | 3-4-5-6-7-8 | G-A-A-A-G-G | 0.085 | −4.92 | 1.99 | |
| rs55700740|rs7542294|rs946259|rs880633|rs1538372|rs4950881 | 1-2-3-4-5-6 | C-G-G-A-A-G | 0.242 | −4.6 | 1.66 | |
| rs7542294|rs946259|rs880633|rs1538372|rs4950881|rs10399805 | 2-3-4-5-6-7 | G-G-A-A-G-G | 0.242 | −4.12 | 1.65 | |
| rs946259|rs880633|rs1538372|rs4950881|rs10399805|rs6691378 | 3-4-5-6-7-8 | G-A-A-G-G-G | 0.242 | 1.66 | 0.025 | |
| rs880633|rs1538372|rs4950881|rs10399805|rs6691378|rs946261 | 4-5-6-7−8-9 | A-A-G-G-G-G | 0.151 | −9.56 | 1.58 | |
| rs946259|rs880633|rs1538372|rs4950881|rs10399805|rs6691378 | 3-4-5-6-7-8 | A-G-G-A-G-G | 0.505 | 1.94 | 0.0317 | |
| rs1538372|rs4950881|rs10399805|rs6691378|rs946261|rs946262 | 5-6-7-8-9-10 | G-A-A-A-G-G | 0.134 | −5.28 | 1.86 | |
| rs4950881|rs10399805|rs6691378|rs946261|rs946262|rs116415868 | 6-7-8-9-10-11 | A-A-A-G-G-G | 0.139 | −5.44 | 1.98 | |
| rs880633|rs1538372|rs4950881|rs10399805|rs6691378|rs946261 | 4-5-6-7-8-9 | A-A-G-G-G-A | 0.090 | 1.83 | 0.020 | |
| rs10399805|rs6691378|rs946261|rs946262|rs116415868|rs10920579 | 7-8-9-10-11-12 | G-G-A-G-G-G | 0.600 | 3.54 | 0.025 |
823 samples, including 631 cases and 194 controls, were analyzed. Mean age = 13.38. Regression analysis was used. Only P values < 0.05 are shown. P values < 0.017 (Bonferroni correction threshold) are in bold. Freq = haplotype frequency; Coeff = coefficient (only shown when corrected P values < 0.05).
Haplotype association analyses of plasma YKL-40 levels in endophenotype 1.
| SNP IDs | SNPs | Haplotype | Freq | Coeff | Std. Error | Pr(>|t|) |
|---|---|---|---|---|---|---|
| rs880633|rs1538372|rs4950881|rs10399805|rs6691378|rs946261 | 4-5-6-7-8-9 | A-A-G-G-G-G | 0.117 | −11.42 | 3.93 | |
| rs1538372|rs4950881|rs10399805|rs6691378|rs946261|rs946262 | 5-6-7-8-9-10 | A-G-G-G-G-A | 0.132 | 11.11 | 0.03 | |
| rs1538372|rs4950881|rs10399805|rs6691378|rs946261|rs946262 | 5-6-7-8-9-10 | A-A-G-G-G-G | 0.039 | 12.12 | 0.035 | |
| rs10399805|rs6691378|rs946261|rs946262|rs116415868|rs10920579 | 7-8-9-10-11-12 | G-G-G-G-G-G | 0.055 | 4.83 | 0.034 |
137 samples (16 males and 111 females) were analyzed. Mean age = 13.48. Regression analysis was used. Only P values < 0.05 are shown. P values < 0.017 (Bonferroni correction threshold) are in bold.
Haplotype association analyses of plasma YKL-40 levels in endophenotype 2.
| SNPs IDs | SNPs | Haplotypes | Freq | Coeff | Std. Error | Pr(>|t|) |
|---|---|---|---|---|---|---|
| rs880633|rs1538372|rs4950881|rs10399805|rs6691378|rs946261 | 4-5-6-7-8-9 | A-A-G-G-G-G | 0.174 | −13.53 | 2.99 | |
| rs4950881|rs10399805|rs6691378|rs946261|rs946262|rs116415868 | 6-7-8-9-10-11 | A-G-G-G-A-G | 0.043 | 8.31 | 3.38 | |
| rs10399805|rs6691378|rs946261|rs946262|rs116415868|rs10920579 | 7-8-9-10-11-12 | G-G-G-A-G-G | 0.045 | 8.85 | 3.25 | |
| rs10399805|rs6691378|rs946261|rs946262|rs116415868|rs10920579 | 7-8-9-10-11-12 | G-G-A-G-G-G | 0.544 | 34.03 | 11.05 |
222 samples (25 males and 197 females) were analyzed. Mean age = 13.78. Regression analysis was used. Only P values < 0.05 are shown. P values < 0.017 (Bonferroni correction threshold) are in bold.
Haplotype association analyses of plasma YKL-40 levels in endophenotype 3.
| SNP IDs | SNPs | Haplotype | Freq | Coeff | Std. Error | Pr(>|t|) |
|---|---|---|---|---|---|---|
| rs880633|rs1538372|rs4950881|rs10399805|rs6691378|rs946261 | 4-5-6-7-8-9 | A-A-G-G-G-G | 0.141 | −19.14 | 8.80 | 0.031 |
| rs4950881|rs10399805|rs6691378|rs946261|rs946262|rs116415868 | 6-7-8-9-10-11 | G-G-G-G-A-G | 0.133 | −11.42 | 3.47 | |
| rs10399805|rs6691378|rs946261|rs946262|rs116415868|rs10920579 | 7-8-9-10-11-12 | G-G-G-A-G-G | 0.19 | 7.94 | 3.86 | |
| rs55700740|rs7542294|rs946259|rs880633|rs1538372|rs4950881 | 1-2-3-4-5-6 | C-G-G-A-A-G | 0.241 | −6.66 | 2.30 | |
| rs880633|rs1538372|rs4950881|rs10399805|rs6691378|rs946261 | 4-5-6-7-8-9 | A-G-A-G-G-A | 0.017 | −36.07 | 8.03 | |
| rs880633|rs1538372|rs4950881|rs10399805|rs6691378|rs946261 | 4-5-6-7-8-9 | G-G-A-G-G-A | 0.480 | 36 | 7.87 | |
| rs4950881|rs10399805|rs6691378|rs946261|rs946262|rs116415868 | 6-7-8-9-10-11 | A-G-G-G-A-G | 0.038 | 9.41 | 3.89 | |
| rs10399805|rs6691378|rs946261|rs946262|rs116415868|rs10920579 | 7-8-9-10-11-12 | A-A-G-G-G-G | 0.134 | −12.53 | 3.48 |
266 samples (54 males and 212 females) were analyzed. Mean age = 13.69. Regression analysis was used. Only P values < 0.05 are shown. P values < 0.017 (Bonferroni correction threshold) are in bold.
Haplotype association analyses of plasma YKL-40 levels in females.
| SNPs IDs | SNPs | Haplotypes | Freq | Coeff | Std. Error | Pr(>|t|) |
|---|---|---|---|---|---|---|
| rs55700740|rs7542294|rs946259|rs880633|rs1538372|rs4950881 | 1-2-3-4--5-6 | C-G-G-A-A-A | 0.078 | 2.44 | 0.021 | |
| rs946259|rs880633|rs1538372|rs4950881|rs10399805|rs6691378 | 3-4-5-6-7-8 | G-A-A-A-G-G | 0.092 | 2.30 | 0.035 | |
| rs4950881|rs10399805|rs6691378|rs946261|rs946262|rs116415868 | 6-7-8-9-10-11 | A-G-G-G-A-G | 0.040 | 6.813 | 2.15 | |
| rs10399805|rs6691378|rs946261|rs946262|rs116415868|rs10920579 | 7-8-9-10-11-12 | G-G-G-A-G-G | 0.029 | 7.902 | 2.08 | |
| rs1538372|rs4950881|rs10399805|rs6691378|rs946261|rs946262 | 5-6-7-8-9-10 | G-A-A-A-G-G | 0.142 | −5.755 | 2.14 | |
| rs4950881|rs10399805|rs6691378|rs946261|rs946262|rs116415868 | 6--7-8-9-10-11 | A-A-A-G-G-G | 0.146 | −5.563 | 2.23 | |
| rs10399805|rs6691378|rs946261|rs946262|rs116415868|rs10920579 | 7-8-9-10-11-12 | A-A-G-G-G-G | 0.146 | −8.425 | 1.78 | |
| rs946259|rs880633|rs1538372|rs4950881|rs10399805|rs6691378 | 3-4-5-6-7-8 | A-G-G-A-G-G | 0.491 | 2.27 | 0.033 | |
| rs880633|rs1538372|rs4950881|rs10399805|rs6691378|rs946261 | 4-5-6-7-8-9 | A-A-G-G-G-A | 0.088 | 6.003 | 2.13 | |
| rs880633|rs1538372|rs4950881|rs10399805|rs6691378|rs946261 | 4-5-6-7-8-9 | A-A-G-G-G-G | 0.153 | −10.08 | 1.90 |
639 samples (534 cases and 105 controls) were analyzed. Mean age = 13.43. Regression analysis was used. Only P values < 0.05 are shown. P values < 0.017 (Bonferroni correction threshold) are in bold.
Haplotype association analyses of plasma YKL-40 levels in males.
| SNPs | SNPs | Haplotypes | Freq | Coeff | Std. Error | Pr(>|t|) |
|---|---|---|---|---|---|---|
| rs55700740|rs7542294|rs946259|rs880633|rs1538372|rs4950881 | 1-2-3-4-5-6 | C-G-G-A-A-G | 0.242 | −6.98 | 2.86 | |
| rs7542294|rs946259|rs880633|rs1538372|rs4950881|rs10399805 | 2-3-4-5-6-7 | G-G-A-A-G-G | 0.242 | 2.90 | 0.021 | |
| rs946259|rs880633|rs1538372|rs4950881|rs10399805|rs6691378 | 3-4-5-6-7-8 | G-A-A-G-G-G | 0.238 | 2.89 | 0.049 | |
| rs880633|rs1538372|rs4950881|rs10399805|rs6691378|rs946261 | 4-5-6-7-8-9 | A-A-G-G-G-G | 0.143 | −9.01 | 2.88 |
186 Samples (97 cases and 89 controls) were analyzed. Mean age = 13.20. Only P values < 0.05 are shown. P values < 0.017 (Bonferroni correction threshold) are in bold.
Figure 3YKL-40 rescues Gi-coupled receptor signalling defect induced by rOPN. Primary osteoblasts obtained from three scoliotic patients were pre-treated with purified rOPN (0.5 µg/ml) with and without rYKL-40 (0.5 µg/ml) for 18 h prior to the stimulation with 10 µM of oxymethazolin. Error bars show SEM of independent experiments performed three times in duplicate. Data represent the percentage of the maximum impedance measured by CDS assay and were normalised to the response achieved in the absence of rOPN (vehicle only). *P < 0.01 based on one-way ANOVA followed by in post-hoc test of Dunnett.